Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.57 |
| ▸ | CLK1 | P49759 | 8/20 | 0.57 |
| ▸ | KIF20A | O95235 | 11/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301105 | 0.92 | PIP4K2A (0.76) | PIP4K2ADYRK1ACLK1KIF20ATDO2 | |
| SCHEMBL18301106 | 0.92 | PIP4K2A (0.76) | PIP4K2ADYRK1ACLK1KIF20ATDO2 | |
| SCHEMBL18301129 | 0.88 | PIP4K2A (0.76) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL18301130 | 0.88 | PIP4K2A (0.76) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL18301172 | 0.86 | PIP4K2A (1.00) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL18301135 | 0.86 | PIP4K2A (1.00) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL18301194 | 0.85 | PIP4K2A (0.72) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL18301195 | 0.85 | PIP4K2A (0.72) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL20293921 | 0.83 | PIP4K2A (0.74) | PIP4K2ADYRK1ACLK1KIF20ACLK2 | |
| SCHEMBL20293910 | 0.82 | PIP4K2A (0.70) | PIP4K2ADYRK1ACLK1KIF20ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | claimed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | claimed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | claimed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | PIP4K2A 2352/4885DYRK1A 1879/4885CLK1 1998/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | PIP4K2A 2352/4885DYRK1A 1879/4885CLK1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.